Insmed (INSM) Misses Q2 EPS by 70c ; Offers Guidance
Tweet
Share
E-mailGet Alerts INSM Hot Sheet
Price: $126.29 -0.31%
Revenue Growth %: +253.1%
Financial Fact:
Interest expense: -769K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +253.1%
Financial Fact:
Interest expense: -769K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Insmed (NASDAQ: INSM) reported Q2 EPS of ($1.94), $0.70 worse than the analyst estimate of ($1.24). Revenue for the quarter came in at $90.3 million versus the consensus estimate of $87.95 million.
GUIDANCE:
Insmed sees FY2024 revenue of $340-360 million, versus the consensus of $353.2 million.
For earnings history and earnings-related data on Insmed (INSM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- FDA grants accelerated approval to AstraZeneca's camizestrant combo
- Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
